Why it isn’t morbid to think about death - CNN

US defence secretary Pete Hegseth’s plan to livestream the execution of Nidal Malik Hasan has incurred condemnation from human rights groups and politicians on all sides. But according to Coltan Scrivner, an author and psychologist at Arizona State University and expert on morbid curiosity, people are still likely to watch in large numbers. He explains why we are drawn to dark and disturbing content, and Madeleine Finlay tells Ian Sample how consuming this kind of material can harm observers’ mental health

We’re sharing this article early to provide faster access to peer-reviewed, accepted research. It is citable and carries a permanent DOI. This version is subject to further edits and will be replaced automatically by the final Version of Record. All legal disclaimers apply. AbstractBunyamwera virus (BUNV) is the prototypical member of the Peribunyaviridae family of arthropod-borne viruses and possesses a genome comprising three segments of negative-sense RNA, named small, medium and large. The medium segment encodes a polyprotein that is processed to form Gn and Gc spikes and a non-structural protein, NSm. The role of NSm during replication in mammalian cells is poorly characterized, although it associates with a Golgi-derived structure called the virus factory (VF), the site of BUNV genome replication and virion assembly. To further define NSm function, we generated an epitope-tagged BUNV and used co-immunoprecipitation and quantitative proteomics to identify host interacting partners.

Scientists co-led by St. Jude Children's Research Hospital have identified a potential therapeutic vulnerability in some forms of osteosarcoma. Published today in the Journal of Experimental Medicine, a combination approach slowed tumor growth and prolonged survival in preclinical models of this pediatric bone cancer. The therapies degraded EP300 (a protein that is co-opted to express oncogenes in many cancers) and inhibited AKT (a well-known cancer drug target), highlighting the combination's clinical potential. Osteosarcoma has lower survival compared to many other cancers, with relapsed and metastatic disease showing especially poor outcomes. As no new treatments have been approved for the disease in the last 40 years, the findings provide a much-needed new therapeutic avenue to explore.